<DOC>
	<DOCNO>NCT03058822</DOCNO>
	<brief_summary>A Phase 1 , relative bioavailability study BMS-931699 prefilled syringe compare drug vial</brief_summary>
	<brief_title>Relative Bioavailability BMS-931699 From Prefilled Syringe Compared Drug Vial</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<criteria>Healthy participant determine clinically significant deviation normal medical history , physical examination , electrocardiogram , clinical laboratory determination All participant must hemoglobin , hematocrit , platelet within normal limit screen All participant must activate partial thromboplastin time , prothrombin time , international normalize ratio within normal limit screen Any current past history risk tuberculosis : Active tuberculosis require treatment within previous 3 year . All participant require QuantiFERON tuberculosis Gold TSPOT tuberculosis test perform screening . Also exclude participant evidence past tuberculosis infection without documented adequate therapy . Participants positive QuantiFERON tuberculosis Gold TSPOT tuberculosis test screen eligible study . A QuantiFERON tuberculosis Gold TSPOT tuberculosis test perform within 4 week dose Day 1 acceptable long documentation negative result . Current clinical , radiographic , laboratory evidence active tuberculosis A history herpes zoster</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>